New hope for cancer patients: Kidney-Sparing drug shows promise
NCT ID NCT07224776
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests a drug called sparsentan to reduce high levels of protein in the urine (proteinuria) caused by certain cancer treatments. About 20 adults with cancer who are taking VEGF inhibitors and have developed proteinuria will receive sparsentan for 8 weeks. The goal is to see if the drug can lower protein levels and help patients stay on their cancer therapy without kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Teen diabetes study seeks to uncover hidden triggers of kidney damage
- New combo therapy may shield diabetic kidneys from damage
- Can a phone app slow kidney disease? new trial aims to find out
- Computer alert aims to catch kidney disease early
- Can a herbal remedy fix kidney side effects of cancer drugs?
- Can a traditional chinese granule ease a common cancer treatment side effect?